Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study developed and validated a mass spectrometric method to measure hydroxy-androgens in serum, which aids in understanding androgen synthesis in castration resistant prostate cancer.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

In this case study, biotin supplementation was reported to interfere with free testosterone assay results, leading to falsely low readings in a postmenopausal woman with hyperandrogenism.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that preparing finasteride as a nanosuspension increased its aqueous solubility by more than 2.5 times, potentially enhancing drug bioavailability.

This study identified a novel class of nonsteroidal ligands that can mimic the effects of dihydrotestosterone on androgen receptors, suggesting potential therapeutic applications in male fertility and hormone replacement therapy.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This study found that LC-MS/MS assays provided more reliable and precise steroid measurements in human serum compared to traditional immunoassays, particularly at lower concentrations.

This study found that the proposed LC-MS/MS method accurately quantified the drug content in split tablets of finasteride and terbinafine, revealing significant variability and suggesting that non-scored tablets should not be split.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This study observed that the isotope-dilution GC-MS technique can assess 5α-reductase activity more effectively than conventional methods in rat liver S9 fractions, particularly at low testosterone levels.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

This study observed that the ethyl acetate extract of Equisetum debile showed high activity against 5α-reductase and lipid peroxidation with no cytotoxicity on dermal papilla cells.

This manuscript explores the development and future potential of injectable biomimetic gels in biomedical applications, highlighting their promise in wound healing and tissue regeneration, while also acknowledging challenges like mechanical durability and scalable production still persist.

In this study, researchers developed ionizable coenzyme Q10-engineered lipid/fiber microplexes that restored mitochondrial-ribosomal function and enhanced mRNA translation in senescent cells, leading to increased hair follicle density and bone formation in mouse models compared to conventional lipid nanoparticles.

This study found that the dimethyl-β-cyclodextrin inclusion system significantly improved the solubility and bioavailability of finasteride compared to the drug alone, enhancing its absorption rate.

This study found that finasteride ethosome formulations with specific ethanol and soya lecithin concentrations significantly enhanced transdermal drug delivery compared to a potential nanogel.

This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.

In this study, researchers formulated a topical gel containing β-sitosterol for alopecia treatment and found it demonstrated good 5 alpha reductase inhibitory activity in vitro, comparable to a commercial product, indicating its potential for further antiandrogenic activity investigation.

This study found that the dissolution profiles of different finasteride polymorphs may affect the quality of finasteride capsules, highlighting the need for polymorphic quality control.

This study found that blood and milk somatic cells show promise as matrices for monitoring illicit recombinant bovine somatotropin use in dairy cattle through gene-expression assays.

This article discusses the FDA approval history of finasteride and does not report new research findings.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.